Biotechnology - Licensing, Financial

Filter

Current filters:

LicensingFinancial

Popular Filters

1 to 25 of 51 results

Cytos Biotech to wind down key operational activities

05-05-2014

Switzerland-based Cytos Biotechnology has entered into agreements with major creditors resulting in a…

BiotechnologyCYT003Cytos BiotechnologyFinancialLicensingRespiratory and Pulmonary

Epizyme earns $4 million milestone under GSK collaboration

22-04-2014

US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…

BiotechnologyEpizymeFinancialGlaxoSmithKlineLicensingOncology

Robust 2013 for biotech licensing deals; average up-front payment jump 60%

28-03-2014

Biotech licensing deals have been trending up markedly in recent months, according to the new installment…

BiotechnologyFinancialLicensing

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

17-03-2014

French biotech firm TxCell SA and privately-held Switzerland-headquartered Ferring International have…

BiotechnologyFerring PharmaceuticalsFinancialGastro-intestinalsLicensingOvaSaveTxCell

Another milestone for GenVec in hearing and balance collaboration

13-02-2014

US biotech firm GenVec says it has achieved the third milestone in its collaboration with Swiss drug…

BiotechnologyCGF166FinancialGenVecLicensingNeurologicalNovartis

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

23-01-2014

Clinical-stage biotech firm Prothena said today that it will receive the $30 million upfront payment…

BiotechnologyFinancialLicensingNeurologicalProthenaPRX002Roche

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Mersana Therapeutics reaches second preclinical milestone in Endo collaboration

10-01-2014

Privately-held US biotech company Mersana Therapeutics has achieved its second preclinical milestone…

BiotechnologyEndo PharmaceuticalsFinancialLicensingMersanaOncologyResearchUSA

Strong third quarter for early-stage biotech licensing deals

27-11-2013

Life sciences companies enjoyed a healthy surge in licensing deals during third quarter 2013, according…

BiotechnologyFinancialLicensing

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Vertex sells Incivo royalty rights to Janssen for $152 million

21-11-2013

Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

MorphoSys closes on the alliance with Celgene

14-08-2013

German biotech firm MorphoSys (FSE: MOR) that its MOR202 alliance with Celgene (Nasdaq: CELG), the world's…

BiotechnologyCelgeneFinancialLicensingMOR202MorphoSysOncology

Tengion closes deals to advance organ regeneration platform

09-07-2013

USA-based Tengion (OTCQB: TNGN), a leader in regenerative medicine, says it has now closed transactions…

BiotechnologyCelgeneFinancialLicensingResearchTengion

Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill

07-06-2013

A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

Medigene secures SynCore as global partner for EndoTAG-1

02-06-2013

German biotech firm Medigene (MDG: GR) has secured SynCore Biotechnology (part of Taiwan's Sinphar Pharmaceutical…

BiotechnologyEndoTAG-1FinancialLicensingMedigeneSynCore Biotechnology

Neovacs moving forward in rheumatoid arthritis, say analysts

17-05-2013

French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead…

Anti-Arthritics/RheumaticsBiotechnologyFinancialLicensingNeovacsResearch

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs

13-05-2013

US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Regeneron acquires rights to two ophthalmology programs from Sanofi

03-05-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…

BiotechnologyEyleaFinancialLicensingOphthalmicsPharmaceuticalRegeneronSanofi

Two life sciences IPOs and strengthening markets offer encouragement to Biotech sector

04-04-2013

Two companies focused on infectious disease successfully completed initial public offerings (IPOs) in…

BiotechnologyFinancialLicensingMergers & Acquisitions

RXi Pharma and OPKO Health pooling RNAi assets

08-03-2013

US biotech firm RXi Pharmaceuticals (Nasdaq: RXII) and OPKO Health (NYSE: OPK) have entered into a strategic…

BiotechnologyFinancialLicensingOPKO HealthPharmaceuticalRXi Pharmaceuticals

Spain's Zeltia is turning a corner, say Edison analysts

28-02-2013

Spanish drugmaker Grupo Zeltia (ZEL: MC) is approaching a material catalyst this year in the form of…

BiotechnologyFinancialLicensinglurbinectedinOncologyPharmaceuticalResearchYondelisZeltia

Infinity amends PI3K-delta, gamma accord with Millennium

28-12-2012

US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

1 to 25 of 51 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top